A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

ClinicalTrials.gov ID: NCT01751152

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01751152. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn's disease.

Study identification

NCT ID: NCT01751152
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novo Nordisk A/S; Industry
Enrollment: 53 participants

Conditions and interventions

Conditions

Interventions

NNC0114-0006 Drug
placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2013 (Type not available)
Primary completion: Dec 2014 (Actual)
Completion: Dec 2014 (Actual)
Last update posted: Mar 31, 2017

2013 – 2014

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Novo Nordisk Investigational Site	Tucson	Arizona	85710	—
Novo Nordisk Investigational Site	Little Rock	Arkansas	72205	—
Novo Nordisk Investigational Site	Little Rock	Arkansas	72212	—
Novo Nordisk Investigational Site	Laguna Hills	California	92653	—
Novo Nordisk Investigational Site	Clearwater	Florida	33759	—
Novo Nordisk Investigational Site	Miami	Florida	33136	—
Novo Nordisk Investigational Site	Jefferson City	Missouri	65109	—
Novo Nordisk Investigational Site	Jackson	Tennessee	38305	—
Novo Nordisk Investigational Site	Houston	Texas	77062	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01751152, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 31, 2017 · Synced Nov 13, 2026